Thursday, March 23, 2023
Village Voice News
ADVERTISEMENT
  • Home
  • News
  • Sports
  • Editorial
  • Letters
  • Global
  • Columns
    • Eye On Guyana
    • Hindsight
    • Lincoln Lewis Speaks
    • Future Notes
    • Blackout
    • From The Desk of Roysdale Forde SC
    • Diplomatic Speak
    • Mark’s Take
    • In the village
    • Mind Your Business
    • Bad & Bold
    • The Voice of Labour
    • The Herbal Section
    • Politics 101 with Dr. David Hinds
    • Talking Dollars & Making Sense
    • Book Review 
  • Education & Technology
  • E-Paper
  • Contact Us
No Result
View All Result
  • Home
  • News
  • Sports
  • Editorial
  • Letters
  • Global
  • Columns
    • Eye On Guyana
    • Hindsight
    • Lincoln Lewis Speaks
    • Future Notes
    • Blackout
    • From The Desk of Roysdale Forde SC
    • Diplomatic Speak
    • Mark’s Take
    • In the village
    • Mind Your Business
    • Bad & Bold
    • The Voice of Labour
    • The Herbal Section
    • Politics 101 with Dr. David Hinds
    • Talking Dollars & Making Sense
    • Book Review 
  • Education & Technology
  • E-Paper
  • Contact Us
No Result
View All Result
Village Voice News
No Result
View All Result
Home Global

New drug for Alzheimer’s expected this week

Admin by Admin
January 3, 2023
in Global
New Scientist Photo

New Scientist Photo

0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

READ ALSO

For shared human values: Forum on democracy opens in Beijing

China discovers huge gold deposit worth $3 billion

Support Village Voice News With a Donation of Your Choice.

The US Food and Drug Administration  (FDA) may likely  decide to grant accelerated approval to the experimental dementia drug named Lecanemab. The drug, manufactured by drug companies Eisai and Biogen, is one of the first medications that shows significant promise in the treatment of Alzheimer’s disease.
Eisai spokesperson Libby Holman confirmed that

“If lecanemab is approved by the FDA under the Accelerated Approval Pathway, Eisai will do its best to make lecanemab available as soon as possible,”

The American Alzheimer’s Disease Association expects the FDA to announce a decision by January 6.
Maria Carillo, the association’s science officer said, We believe, based on the totality of positive data from clinical trials of this treatment, that the FDA should approve. Peer-reviewed, published results show lecanemab will provide patients in the earliest stages of Alzheimer’s more time to participate in daily life and live independently. It could mean many months more of recognizing their spouse, children and grandchildren.”
Alzheimer’s disease is a form of dementia that usually starts with memory loss and gets worse over time. Brain cells die and the brain shrinks which leads to deficits in cognitive functions, such as memory, language skills, and behavior.
Guyana’s health minister Dr. Frank Anthony had spoken about the disease last September during Alzheimer’s Awareness Month.
 
The Minister said, “The estimate right now is that one in six persons between 80 and 85 years of age would have Alzheimer’s or dementia. One in three persons above 85 would have Alzheimer’s, and one in two above 90 would have Alzheimer’s, so age is really an important factor here.”
 
Minister Anthony spoke of the symptoms of the disease. He said, “What we need to look at is initially the disease would present with very subtle changes. So, people start losing their memory gradually, they are not remembering things, you might say something to them, they forget what you have just said to them, they repeat themselves, so they may tell you something now, repeat that a little, a few minutes, so they can’t remember what they have said to you.”
Dr. Anthony noted that, “It’s very important that if you find that an older relative or someone in your care is having these signs and symptoms, is for them to come to the hospital so that the doctors can make that diagnosis and probably advise on treatment and be able to give you better advice on how to care for these persons.”
 
Meanwhile, clinical trials of the drug indicate that there may be side effects The most common adverse events in the lecanemab group were reactions to the intravenous infusions and abnormalities on their MRIs, such as brain swelling and bleeding called amyloid-related imaging abnormalities, or ARIA, which can become life threatening.
Experts assure that even after the drug is approved, patients will be monitored and studies of the medication’s effects will continue. However, experts across the medical community report excitement and optimism regarding the drug’s potential benefits.



Support Village Voice News With a Donation of Your Choice



ShareTweetSendShareSend

Related Posts

The Second International Forum on Democracy: The Shared Human Values kicks off in Beijing, China, March 23, 2023. /CMG
Global

For shared human values: Forum on democracy opens in Beijing

by Admin
March 23, 2023

Ahead of the U.S.'s "Summit for Democracy," the Second International Forum on Democracy: The Shared Human Values kicked off on...

Read more
China has recently discovered a gold deposit of nearly 50 tonnes. /CFP
Global

China discovers huge gold deposit worth $3 billion

by Admin
March 23, 2023

China has recently discovered a huge gold deposit with a reserve of nearly 50 tonnes, which can be sold for...

Read more
Candida auris infection  (Getty image)
Global

Candida auris fungal infections spreading in US at ‘alarming’ rate, says CDC

by Admin
March 22, 2023

(BBC News) A deadly fungal infection that is hard to treat is spreading rapidly at an "alarming" rate, says the...

Read more
Next Post
Sulemana Abdul Samed aka Awuche

9 ft. 6in and still growing: The Ghanaian giant reported to be the world’s tallest man

EDITOR'S PICK

3 Caribbean immigrants in the fight for abolition and Civil Rights you should know

June 23, 2022
Former Minister of Finance, Winston Jordan and Attorney General, Anil Nandlall

AG to take legal action against Jordan for land transactions

November 1, 2020

Sri Lanka, West Indies gear up to shake off ODI rust 

March 10, 2021

‘Slowe puts Ali in it’

May 31, 2021

© 2022 Village Voice | Developed by Ink Creative Agency

No Result
View All Result
  • Home
  • News
  • Sports
  • Editorial
  • Letters
  • Global
  • Columns
    • Eye On Guyana
    • Hindsight
    • Lincoln Lewis Speaks
    • Future Notes
    • Blackout
    • From The Desk of Roysdale Forde SC
    • Diplomatic Speak
    • Mark’s Take
    • In the village
    • Mind Your Business
    • Bad & Bold
    • The Voice of Labour
    • The Herbal Section
    • Politics 101 with Dr. David Hinds
    • Talking Dollars & Making Sense
    • Book Review 
  • Education & Technology
  • E-Paper
  • Contact Us

© 2022 Village Voice | Developed by Ink Creative Agency